PaTrin-2 is a more potent MGMT inactivator in vitro than O6-BeG, and we considered it worthwhile to examine the extent to which PaTrin-2 could inactivate MGMT and increase sensitivity to temozolomide in a human breast tumour model as a prerequisite for any potential clinical trial in breast cancer. This evidence concerns the gene MGMT and breast carcinoma.